Jeito Capital Secures Major Financing for Augustine Therapeutics
Jeito Capital, a prominent independent Private Equity fund focused on biopharmaceutical innovations, has co-led an impressive €78 million financing round aimed at advancing the clinical development of Augustine Therapeutics. This funding will play a critical role in bringing new therapies to market that are designed for patients suffering from neuromuscular, cardio-metabolic, and neurodegenerative diseases.
Advancing Groundbreaking Therapies
The funds from this financing are earmarked for advancing Augustine’s lead candidate, AGT-100216, through a Phase 2 proof-of-concept clinical trial targeting Charcot-Marie-Tooth disease (CMT). Beyond this key milestone, the financing will also facilitate further expansion of Augustine's pipeline into other critical areas of need within the realms of cardio-metabolic and neurodegenerative diseases.
Industry Context and Importance
This investment highlights Jeito Capital's unwavering commitment to pioneering advancements in neurology, an area that harbors significant unmet medical needs. Neuromuscular disorders, such as CMT, affect thousands of patients who currently face limited treatment options. Therefore, the financial backing of Jeito presents an opportunity not just for Augustine Therapeutics but also for the broader patient community seeking innovative solutions.
Investment Leadership and Team Expansion
In this round, Jeito Capital and Novo Holdings took the lead, supported by foundational investors like Asabys Partners, Eli Lilly and Company, AdBio Partners, and several others. This collective support underscores the confidence in Augustine’s potential to innovate treatments for conditions that remain challenging to address. As part of this investment, two representatives from Jeito Capital will join Augustine’s Board of Directors, bringing valuable expertise to the company's governance.
Understanding Augustine Therapeutics
Founded in 2019 as a spin-off from the notable research institution VIB-KU Leuven, Augustine Therapeutics has zeroed in on the inhibition of Histone Deacetylase 6 (HDAC6) as a pivotal mechanism for developing effective therapies. HDAC6 plays a crucial role in various cellular processes linked to neurological diseases, presenting a robust target for therapeutic intervention. The company’s approach seeks to advance the understanding and applicability of HDAC6 inhibitors beyond CMT, venturing into additional indications that involve neurodegenerative and cardio-metabolic components.
Looking Forward
Mehdi Ainouche, a Senior Principal at Jeito Capital, has expressed enthusiasm about this collaboration, noting the shared ambition between Jeito and Augustine to enhance clinical development processes. With a focus on rapidly progressing therapies to market, the partnership boasts a vision centered on expediting the timeline for patient access to innovative treatments.
Commitment to Innovation and Patient Care
Dr. Rafaèle Tordjman, Founder and CEO of Jeito Capital, emphasized that this investment demonstrates a deep commitment to advancing medical innovation. He reiterated the importance of focusing on patient needs, stating that through this funding, they can support Augustine in paving the way toward novel therapeutics that could change lives. The expectations surrounding the trial for AGT-100216 are high, and many stakeholders are watching closely as Augustine embarks on this crucial journey.
The Future of Neurological Treatments
As Augustine Therapeutics prepares to initiate clinical trials for its promising lead candidate, expectations remain high that this unique treatment approach could redefine how neurological and metabolic diseases are managed. With a solid financial foundation and a committed team led by Gerhard Koenig, Augustine is positioned to become a significant player in the biopharma landscape.
Frequently Asked Questions
What is the purpose of the €78 million financing?
The financing is aimed at advancing Augustine Therapeutics' lead candidate, AGT-100216, through clinical trials while expanding the therapeutic pipeline.
Who are the key players in this funding round?
The funding round was co-led by Jeito Capital and Novo Holdings, alongside substantial contributions from existing investors such as Eli Lilly and Company.
What is AGT-100216 and its significance?
AGT-100216 is Augustine's lead candidate targeting Charcot-Marie-Tooth disease, aiming to explore novel treatment options for patients suffering from neuropathies.
What role does Jeito Capital play in this process?
Jeito Capital not only provides financial support but also brings expertise and leadership through board representation to guide Augustine's strategic vision and development.
How does Augustine aim to address neurological disorders?
Augustine focuses on the inhibition of HDAC6, leveraging innovative methods to enhance the specificity and effectiveness of treatments directed at neurological and metabolic diseases.
